sumatriptan-naproxen

11/01/2012 - "Combination of sumatriptan/naproxen effectively treats migraine headaches in adolescents."
04/04/2007 - "Sumatriptan-naproxen for acute treatment of migraine: a randomized trial."
01/01/2019 - "Modulation of brain networks by sumatriptan-naproxen in the inflammatory soup migraine model."
04/01/2013 - "Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function."
01/01/2012 - "The number of patients who rated their Overall Satisfaction following treatment with sumatriptan-naproxen as "Satisfied" (satisfied or very satisfied) was 32 (80%) after the first migraine and 25 (63%) after 3 or more migraines. "

03/01/2014 - "In our study, 63.9% of patient attacks treated with sumatriptan/naproxen achieved 2-hour pain freedom compared with 33.3% of those with placebo (P < 0.001). "
03/01/2014 - "With truly episodic migraineurs, pain freedom was significant as soon as 15 minutes following treatment with sumatriptan/naproxen (5.2% vs 0% with placebo; P < 0.01). "
03/01/2014 - "More subjects using sumatriptan/naproxen achieved sustained pain freedom (than 2-hour pain freedom), due to 6 time points when the subject was sleeping/napping 2-hours post dose (5 sumatriptan/naproxen, 1 placebo), yet attested to no discomfort between 2 and 24 hours post dose. "
03/01/2014 - "Sustained pain freedom (2-24 hours) was achieved in 69.1% of sumatriptan/naproxen-treated attacks, compared with 23.3% with placebo (P < 0.01). "
10/01/2011 - "In addition, sumatriptan/naproxen sodium provided freedom from pain over time, improvements in quality of life and medication satisfaction."

04/01/2013 - "Subanalysis showed a correlation between headache severity and Performance Index in the Treximet group but not in the placebo group (∼Fig. ). "
04/01/2013 - "Each patient then was treated for 2 headaches in a cross-over manner with sumatriptan-naproxen (Treximet®) or placebo in a double-blind, placebo-controlled fashion with cognitive testing repeated at 1 and 2 hours post-dose. "
07/01/2009 - "Sumatriptan-naproxen was statistically superior to placebo in both studies (n=311, Study 1; n=310, Study 2) for 2-hour and, 2- to 24-hour sustained pain-free response, use of headache and menstrual rescue medications, and several nonpain menstrual symptom categories. "
07/08/2008 - "Patients treated a single migraine within 1 hour of onset of migraine head pain and while the pain was mild with either sumatriptan/naproxen or placebo. "
03/01/2014 - "Successfully screened adult migraineurs who returned baseline diaries showing 2 to 7 migraine attacks monthly and < 15 headache and/or neck pain days/month received blister packs containing 3 sumatriptan/naproxen/1 placebo for treatment of 4 migraines. "

04/04/2007 - "Sumatriptan-naproxen sodium was more effective than placebo for headache relief at 2 hours after dosing (study 1, 65% vs 28%; P<.001 and study 2, 57% vs 29%; P<.001), absence of photophobia at 2 hours (58% vs 26%; P<.001 and 50% vs 32%; P<.001), and absence of phonophobia at 2 hours (61% vs 38%; P<.001 and 56% vs 34%; P<.001). "
07/08/2008 - "At 2 and 4 hours, sumatriptan/naproxen provided significantly lower rates of traditional migraine-associated symptoms (nausea, photophobia, and phonophobia) and nontraditional migraine-associated symptoms (neck pain/discomfort and sinus pain/pressure). "
07/01/2009 - "In migraineurs who reported poor response to a short-acting triptan, sumatriptan/naproxen sodium was generally well tolerated and significantly more effective than placebo in conferring initial, intermediate, and sustained efficacy for pain and migraine-associated symptoms of photophobia and phonophobia."
04/04/2007 - "Primary outcome measures included the percentages of patients with headache relief 2 hours after dosing, absence of photophobia, absence of phonophobia, and absence of nausea for the comparison between sumatriptan-naproxen sodium and placebo, and the percentages of patients with sustained pain-free response for the comparison between sumatriptan-naproxen sodium and each monotherapy. "

04/04/2007 - "Sumatriptan-naproxen sodium was more effective than placebo for headache relief at 2 hours after dosing (study 1, 65% vs 28%; P<.001 and study 2, 57% vs 29%; P<.001), absence of photophobia at 2 hours (58% vs 26%; P<.001 and 50% vs 32%; P<.001), and absence of phonophobia at 2 hours (61% vs 38%; P<.001 and 56% vs 34%; P<.001). "
07/08/2008 - "At 2 and 4 hours, sumatriptan/naproxen provided significantly lower rates of traditional migraine-associated symptoms (nausea, photophobia, and phonophobia) and nontraditional migraine-associated symptoms (neck pain/discomfort and sinus pain/pressure). "
07/01/2009 - "In migraineurs who reported poor response to a short-acting triptan, sumatriptan/naproxen sodium was generally well tolerated and significantly more effective than placebo in conferring initial, intermediate, and sustained efficacy for pain and migraine-associated symptoms of photophobia and phonophobia."
04/04/2007 - "Primary outcome measures included the percentages of patients with headache relief 2 hours after dosing, absence of photophobia, absence of phonophobia, and absence of nausea for the comparison between sumatriptan-naproxen sodium and placebo, and the percentages of patients with sustained pain-free response for the comparison between sumatriptan-naproxen sodium and each monotherapy. "